louisiana semaglutide gastric stasis class action legal team in glp-1 attorney glp-1 gastric stasis glp-1 gastric stasis law office

1 SELECT: 73% reduction in progression to diabetes The SELECT trial tested semaglutide 2.4 mg in over 17,000 people with established cardiovascular disease and overweight or obesity

GLP-1 treatment reduces phosphorylation of AKT and ERK1/2 induced by oxidative stress

Silva completed residency training in Occupational Medicine, a specialty focused on prevention, workplace health, and injury recovery

Persistent or severe vomiting should be discussed with your prescribing provider to explore management options or timing adjustments

Early-phase data showed significant liver fat reductions in retatrutide-treated participants

Coverage may also be denied if the injections are not documented as medically necessary by a healthcare professional